Ovarian cancer biology.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Seminars in Oncology

• Publication date

  1991-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 2042060
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug resistance and DNA repair

  2004cited by this paper
• A study of the mechanisms of cytotoxicity of Ara-C on three human leukemic cell lines

  2004cited by this paper
• Metallothionein-like proteins and cell resistance tocis-dichlorodiammineplatinum(II) in L1210 cells

  2004cited by this paper
• Short-termcis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells

  2004cited by this paper
• Chromosome aberrations in metastatic ovarian cancer: Relationship with abnormalities in primary tumors

  1990cited by this paper
• Metallothionein gene expression and resistance to cisplatin in human ovarian cancer

  1990cited by this paper
• Estrogen‐ and androgen‐responsive growth of human ovarian adenocarcinoma heterotransplanted into nude mice

  1990cited by this paper
• Cancer statistics, 1990

  1990cited by this paper
• Transforming growth factors and the regulation of cell proliferation.

  1990cited by this paper
• Are myc proteins transcription factors?

  1990cited by this paper
• Transforming growth factor-beta and ovarian carcinoma cells: regulation of proliferation and surface antigen expression.

  1990cited by this paper
• The Role of Peptide Growth Factors in Epithelial Ovarian Cancer

  1990cited by this paper
• Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

  1990cited by this paper
• Changes in glutathione content and resistance to anticancer agents in human stomach cancer cells induced by treatments with melphalan in vitro.

  1990cited by this paper
• Protooncogene amplification and tumor ploidy in human ovarian neoplasms.

  1990cited by this paper
• Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas.

  1990cited by this paper
• Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA.

  1990cited by this paper
• Loss of heterozygosity on chromosomal segments 3p, 6q and 11p in human ovarian carcinomas.

  1990cited by this paper
• Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum

  1990cited by this paper
• Transfer of a normal human chromosome 11 suppresses tumorigenicity of some but not all tumor cell lines

  1990cited by this paper
• More evidence for circadian rhythm effects in cancer chemotherapy: the fluoropyrimidine story.

  1990cited by this paper
• Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).

  1990cited by this paper
• Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma.

  1990cited by this paper
• The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells.

  1990cited by this paper
• Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems.

  1990cited by this paper
• Characterization of a hormone-producing ovarian carcinoma cell line.

  1989cited by this paper
• Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents.

  1989cited by this paper
• Response to inhibition of androgen action of human ovarian cancer cells in vitro.

  1989cited by this paper
• Oncogenes, growth factors, and signal transduction.

  1989cited by this paper
• Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum(II).

  1989cited by this paper
• Estrogen and Anti‐Estrogen Effects on the Growth of Human Epithelial Ovarian Cancer In Vitro

  1989cited by this paper
• Chromosome aberrations in nine patients with ovarian cancer.

  1989cited by this paper
• Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract.

  1989cited by this paper
• Allele loss at the c-Ha-ras1 locus in human ovarian cancer.

  1989cited by this paper
• Amplification of c‐ras‐ki oncogene in human ovarian tumours

  1989cited by this paper
• Mechanisms of resistance to cis-diamminedichloroplatinum (II) in a rat ovarian carcinoma cell line.

  1989cited by this paper
• The occurrence of epidermal growth factor receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer

  1989cited by this paper
• Association of Ki-ras with amplified DNA sequences, detected in human ovarian carcinomas by a modified in-gel renaturation assay.

  1989cited by this paper
• Flow cytometric analysis of DNA content in human ovarian cancers.

  1989cited by this paper
• Flow cytometric measurement of ploidy and proliferation in effusions of ovarian carcinoma and their possible prognostic significance.

  1989cited by this paper
• Quenching of DNA cross-link precursors of chloroethylnitrosoureas and attenuation of DNA interstrand cross-linking by glutathione.

  1989cited by this paper
• 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.

  1989cited by this paper
• P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines.

  1989cited by this paper
• Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis.

  1989cited by this paper
• DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA.

  1989cited by this paper
• Melphalan transport into human malignant lymphoid cells differs from the murine equivalent in vitro.

  1989cited by this paper
• Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia.

  1989cited by this paper
• The p53 proto-oncogene can act as a suppressor of transformation.

  1989cited by this paper
• Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.

  1989cited by this paper
• An overview of tumor biology.

  1989cited by this paper
• Determination of cellular oncogene rearrangement or amplification in ovarian adenocarcinomas.

  1989cited by this paper
• Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases.

  1989cited by this paper
• Report of the committee on structural chromosome changes in neoplasia.

  1989cited by this paper
• Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines.

  1989cited by this paper
• Induction of beta-polymerase mRNA by DNA-damaging agents in Chinese hamster ovary cells

  1989cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Expression of a human multidrug resistance gene in ovarian carcinomas.

  1989cited by this paper
• Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II)

  1989cited by this paper
• cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.

  1988cited by this paper
• Peptide growth factors are multifunctional

  1988cited by this paper
• Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells.

  1988cited by this paper
• Potentiation of DNA damage and cytotoxicity by calmodulin antagonists.

  1988cited by this paper
• ras oncogene activation in human ovarian carcinoma.

  1988cited by this paper
• Serial propagation of human ovarian surface epithelium in tissue culture

  1988cited by this paper
• Onco-suppressor genes and their involvement in cancer (review).

  1988cited by this paper
• In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II).

  1988cited by this paper
• Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome.

  1988cited by this paper
• Prognostic value of the flow cytometric DNA index in human ovarian carcinoma

  1988cited by this paper
• Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

  1988cited by this paper
• Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro.

  1988cited by this paper
• A unique pattern of proto‐oncogene abnormalities in ovarian adenocarcinomas

  1988cited by this paper
• Isolation of a low molecular weight inhibitor of lymphocyte proliferation from tumorous ascites.

  1988cited by this paper
• Enhanced DNA repair and resistance to cisplatin in human ovarian cancer.

  1988cited by this paper
• Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

  1988cited by this paper
• Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines.

  1988cited by this paper
• Overexpression of metallothionein confers resistance to anticancer drugs.

  1988cited by this paper
• Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer.

  1988cited by this paper
• Mechanism of multidrug resistance.

  1988cited by this paper
• Recessive mechanisms of malignancy.

  1988cited by this paper
• cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

  1988cited by this paper
• Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas.

  1988cited by this paper
• DNA repair enzymes.

  1988cited by this paper
• DNA damage-inducible transcripts in mammalian cells.

  1988cited by this paper
• Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts.

  1988cited by this paper
• Oncogenes and tumor-suppressing genes.

  1988cited by this paper
• Deficiency of all or part of chromosome 11 in several types of cancer: significance of a reduction in the number of normal chromosomes 11.

  1988cited by this paper
• Cytogenetic findings in cell lines derived from four ovarian carcinomas.

  1987cited by this paper
• The molecular genetics of cancer.

  1987cited by this paper
• Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

  1987cited by this paper
• W‐7, a calmodulin inhibitor, potentiates dacarbazine cytotoxicity in human neoplastic cells

  1987cited by this paper
• Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

  1987cited by this paper
• Serum CA 125 and survival of mice inoculated with ovarian carcinoma and treated with antiestrogen, estrogen, or progestin.

  1987cited by this paper
• Multiple-drug resistance in human cancer.

  1987cited by this paper
• Enhancement of antineoplastic effects of cisplatin by calmodulin antagonists in nude mice bearing human ovarian carcinoma.

  1987cited by this paper
• High quality metaphases from solid ovarian tumors.

  1987cited by this paper
• Heterogeneous DNA damage and repair in the mammalian genome.

  1987cited by this paper
• Dietary factors and the risk of epithelial ovarian cancer.

  1987cited by this paper
• Decreased cisplatin uptake by resistant L1210 leukemia cells.

  1987cited by this paper
• Tumor markers in the human ovary and its neoplasms. A comparative immunohistochemical study.

  1987cited by this paper
• Specificity of proto-oncogene amplification in human malignant diseases.

  1987cited by this paper

• [Activation of JAK/STAT in ovarian high-grade serous cancers and its prognostic significance].

  2023cites this paper
• Potential of peptide‐engineered exosomes with overexpressed miR‐92b‐3p in anti‐angiogenic therapy of ovarian cancer

  2021cites this paper
• Mechanisms and pathobiology of ovulation.

  2019cites this paper
• Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer

  2019cites this paper
• Ovarian cancer: avoiding compromising quality of life during intense chemotherapy sessions

  2016cites this paper
• HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation

  2016cites this paper
• Malignant ascites in ovarian cancer and the role of targeted therapeutics.

  2014cites this paper
• Phosphatidylinositol 3‐kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines

  2014cites this paper
• Fibronectin promotes migration and invasion of ovarian cancer cells through up‐regulation of FAK–PI3K/Akt pathway

  2014cites this paper
• Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers

  2013cites this paper
• Oral Administration of Apigenin Inhibits Metastasis through AKT/P70S6K1/MMP-9 Pathway in Orthotopic Ovarian Tumor Model

  2012cites this paper
• Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.

  2012cites this paper
• RNAi knockdown of the Akt1 gene increases the chemosensitivity of gastric cancer cells to cisplatin both in vitro and in vivo.

  2012cites this paper
• Cancer Therapy : Preclinical TGF-b Blockade Controls Ascites by Preventing Abnormalization of Lymphatic Vessels in Orthotopic Human Ovarian Carcinoma Models

  2011cites this paper
• Die Rolle des VEGF im Ovarialkarzinom

  2011cites this paper
• TGF-β Blockade Controls Ascites by Preventing Abnormalization of Lymphatic Vessels in Orthotopic Human Ovarian Carcinoma Models

  2011cites this paper
• Therapeutic Targeting of PELP1 Prevents Ovarian Cancer Growth and Metastasis

  2011cites this paper
• Therapeutic targeting of PELP 1 prevents ovarian cancer growth and metastasis

  2011cites this paper
• Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc

  2010cites this paper
• Whole ovary immunohistochemistry for monitoring cell proliferation and ovulatory wound repair in the mouse

  2010cites this paper
• VEGF antibody plus cisplatin reduces angiogenesis and tumor growth in a xenograft model of ovarian cancer.

  2010cites this paper
• CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.

  2009cites this paper
• Kaempferol Inhibits Angiogenesis and VEGF Expression Through Both HIF Dependent and Independent Pathways in Human Ovarian Cancer Cells

  2009cites this paper
• Autocrine VEGF‐A/KDR loop protects epithelial ovarian carcinoma cells from anoikis

  2009cites this paper
• Ovulatory factor in ovarian carcinogenesis.

  2008cites this paper
• Role of PELP1/MNAR signaling in ovarian tumorigenesis.

  2008cites this paper
• Inhibition of Cell Growth and VEGF Expression in Ovarian Cancer Cells by Flavonoids

  2008cites this paper
• Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts.

  2008cites this paper
• A BRIEF COMMUNICATION

  2007influential citation
• 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit ovarian cancer cell growth through peroxisome proliferator–activated receptor–dependent and independent pathways

  2006cites this paper
• The expression and function of secreted frizzled-related protein 4 in human serous ovarian carcinoma

  2006cites this paper
• Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.

  2006cites this paper
• Carcinogenic Potential of Ovulatory Genotoxicity1

  2005cites this paper
• A BRIEF COMMUNICATION

  2005cites this paper
• Significance of Fas receptor protein expression in epithelial ovarian cancer.

  2005cites this paper
• 19 - Role of Immunohistochemical Expression of Lewis Y Antigen in Ovarian Carcinoma

  2005cites this paper
• Apigenin inhibits VEGF and HIF‐1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways

  2005cites this paper
• Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.

  2005cites this paper
• Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up

  2005cites this paper
• VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma.

  2004cites this paper
• SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway.

  2004cites this paper
• trans-3,4,5′-Trihydroxystibene Inhibits Hypoxia-Inducible Factor 1α and Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells

  2004cites this paper
• CHAPTER 36 – Ovarian Carcinogenesis

  2004cites this paper
• Oxidative Damage to DNA of Ovarian Surface Epithelial Cells Affected by Ovulation: Carcinogenic Implication and Chemoprevention

  2004cites this paper
• CHAPTER 18 – Ovarian Angiogenesis

  2004cites this paper
• P53 Expression, Dna Ploidy and Mitotic Index as Prognostic Factors in Patients with Epithelial Ovarian Carcinoma

  2004cites this paper
• p53 and erbB-2 Are Not Associated in Matched Cases of Primary and Metastatic Ovarian Carcinomas

  2004cites this paper
• G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.

  2004cites this paper
• Translational research in ovarian cancer: a must

  2003cites this paper
• CHAPTER 31 – Ovarian Cancer: The Initial Laparotomy

  2003cites this paper
• Inhibitory Effects of Progesterone on Plasma Membrane Fluidity and Tumorigenic Potential of Ovarian Epithelial Cancer Cells

  2003cites this paper
• Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma.

  2003cites this paper
• A novel laminin‐induced lysophosphatidic acid autocrine loop in the migration of ovarian cancer cells

  2003cites this paper
• Vascular endothelial growth factor in females of reproductive age

  2003cites this paper
• Shed Membrane Fragment-Associated Markers for Endometrial and Ovarian Cancers

  2002cites this paper
• Angiogenesis in epithelian ovarian cancer

  2002cites this paper
• Steroid hormonal regulation of proliferative, p53 tumor suppressor, and apoptotic responses of sheep ovarian surface epithelial cells.

  2002cites this paper
• Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility.

  2002cites this paper
• Shed membrane fragment-associated markers for endometrial and ovarian cancers.

  2002cites this paper
• Premenstrual syndrome

  2002cites this paper
• Roles of the ovarian surface epithelium in ovulation and carcinogenesis.

  2002influential citation
• Ovulation-Induced DNA Damage in Ovarian Surface Epithelial Cells of Ewes: Prospective Regulatory Mechanisms of Repair/Survival and Apoptosis1

  2001cites this paper
• High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane.

  2001cites this paper
• Role of vascular endothelial growth factor in ovarian physiology and pathology.

  2000cites this paper
• Intraperitoneal Radioimmunotherapy of Ovarian Cancer: Radiobiological Basis, Clinical Status and Future Prospects

  2000cites this paper
• In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).

  2000cites this paper
• Role of endothelin-1 in neovascularization of ovarian carcinoma.

  2000cites this paper
• Proteolytic and Cellular Death Mechanisms in Ovulatory Ovarian Rupture

  2000cites this paper
• In Vivo and in Vitro Ovarian Carcinoma Growth Inhibition by a Phosphatidylinositol 3-Kinase Inhibitor ( LY 294002 ) 1

  2000cites this paper
• Mesothelial cells induce the motility of human ovarian carcinoma cells

  1999cites this paper
• Etiology of ovarian cancer: a proposed mechanism.

  1999cites this paper
• Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer

  1999cites this paper
• Cytotoxicity of two novel cisplatin analogues, (CPA)2Pt[DOLYM] and (DACH)Pt[DOLYM], to human cancer cellsin vitro

  1999cites this paper
• Evaluation of the tyrosine kinase domain of theMet Proto-oncogene in sporadic ovarian carcinomas

  1999cites this paper
• Induction of apoptosis and suppression of clonogenicity of ovarian carcinoma cells with estrogen mustard

  1999cites this paper
• Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

  1999cites this paper
• Establishment and characterization of a serous papillary adenocarcinoma cell line of the human ovary in a serum-free culture.

  1999cites this paper
• Tumor-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance? (review).

  1998cites this paper
• Il Carcinoma Dell'ovaio Avanzato Stato Dell'arte e Prospettive Future

  1998cites this paper
• [Advanced ovarian cancer: state of the art and future perspectives].

  1998cites this paper
• The biology of ovarian cancer.

  1998cites this paper
• Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization.

  1998cites this paper
• Integrin-mediated adhesion and signalling in ovarian cancer cells.

  1998cites this paper
• Synthesis and biological activity of gold and tin compounds in ovarian cancer cells.

  1998cites this paper
• Activation of Fas ligand/receptor system kills ovarian cancer cell lines by an apoptotic mechanism.

  1998cites this paper
• Expression of cyclin D1 correlates with malignancy in human ovarian tumours.

  1997cites this paper
• Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes.

  1997cites this paper
• Ovarian cancer: natural history and metastatic pattern.

  1997cites this paper
• Induction of Immune Responses to Ovarian Tumor Antigens by Multiparity

  1997cites this paper
• Relationship between heat shock protein 60 (HSP60) mRNA expression and resistance to platinum analogues in human ovarian and bladder carcinoma cell lines.

  1997cites this paper
• Should prophylactic oophorectomy be performed on post-menopausal women undergoing laparotomy or laparoscopy for non-gynaecological indications?

  1997cites this paper
• Ovarian cancer after successful ovulation induction: a case report.

  1996cites this paper
• [Current aspects of ovarian carcinoma].

  1996cites this paper
• Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation.

  1996cites this paper
• OVARIAN SURFACE EPITHELIUM, OVULATION AND CARCINOGENESIS

  1996cites this paper
• Epidermal growth factor receptor gene and c‐erbB‐2 gene amplification in ovarian cyst fluid

  1996cites this paper
• Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases.

  1996cites this paper
• CA 125 in ovarian cysts, serous effusions and peritoneal washings: immunocytochemical expression.

  1995cites this paper
• Ovarian stimulation and ovarian tumours: a critical reappraisal.

  1995cites this paper
• An evaluation of prognostic factors in advanced ovarian cancer.

  1995cites this paper